

Douglas W Sborov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9225004/publications.pdf>

Version: 2024-02-01

33
papers

529
citations

759233

12
h-index

677142

22
g-index

33
all docs

33
docs citations

33
times ranked

859
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 91-95. | 4.9 | 9 |
| 2 | Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. European Journal of Cancer, 2022, , . | 2.8 | 4 |
| 3 | Financial toxicity in hematological malignancies: a systematic review. Blood Cancer Journal, 2022, 12, 74. | 6.2 | 22 |
| 4 | Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma. Clinical Hematology International, 2022, 4, 56-59. | 1.7 | 0 |
| 5 | Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. Therapeutic Advances in Hematology, 2022, 13, 204062072211006. | 2.5 | 4 |
| 6 | MagnetisMM-9: An open-label, multicenter, non-randomized phase 1/2 study of elranatamab in patients with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology, 2022, 40, TPS8068-TPS8068. | 1.6 | 2 |
| 7 | Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. Leukemia, 2021, 35, 189-200. | 7.2 | 56 |
| 8 | A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. Cancer Chemotherapy and Pharmacology, 2021, 87, 599-611. | 2.3 | 16 |
| 9 | Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients. Blood Advances, 2021, 5, 1097-1101. | 5.2 | 15 |
| 10 | Hospitalization at the end of life in patients with multiple myeloma. BMC Cancer, 2021, 21, 339. | 2.6 | 9 |
| 11 | Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo. Molecular Therapy - Oncolytics, 2021, 20, 519-531. | 4.4 | 8 |
| 12 | Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. Lancet Haematology, the, 2021, 8, e299-e304. | 4.6 | 10 |
| 13 | Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review. American Journal of Hematology, 2021, 96, 690-697. | 4.1 | 13 |
| 14 | A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer, 2021, 21, 510. | 2.6 | 21 |
| 15 | Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. Leukemia, 2021, 35, 3526-3533. | 7.2 | 13 |
| 16 | Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. European Journal of Cancer, 2021, 156, 164-174. | 2.8 | 9 |
| 17 | Multiple Myeloma Patients Treated at Academic Centers Have Improved Survival Outcomes. Blood, 2021, 138, 1971-1971. | 1.4 | 1 |
| 18 | Palliative Care Utilization, Transfusion Burden and Symptoms for Patients with Multiple Myeloma at the End of Life. Blood, 2021, 138, 4103-4103. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. <i>Leukemia</i> , 2020, 34, 317-321. | 7.2 | 34 |
| 20 | Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 44-49. | 2.0 | 4 |
| 21 | XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant. <i>Molecular Carcinogenesis</i> , 2019, 58, 2327-2339. | 2.7 | 7 |
| 22 | A Single Nucleotide Polymorphism in <i>SLC7A5</i> Was Associated With Clinical Response in Multiple Myeloma Patients. <i>Anticancer Research</i> , 2019, 39, 67-72. | 1.1 | 10 |
| 23 | Most multiple myeloma patients have low testosterone. <i>Leukemia and Lymphoma</i> , 2019, 60, 836-838. | 1.3 | 3 |
| 24 | Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma. <i>Blood</i> , 2019, 134, 1816-1816. | 1.4 | 1 |
| 25 | Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 748-758. | 2.5 | 11 |
| 26 | Polymorphism in <i>ANRIL</i> is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. <i>Molecular Carcinogenesis</i> , 2017, 56, 1722-1732. | 2.7 | 28 |
| 27 | A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2017, 58, 2310-2318. | 1.3 | 43 |
| 28 | Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 830-841. | 4.1 | 35 |
| 29 | Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma. <i>British Journal of Haematology</i> , 2015, 171, 74-83. | 2.5 | 20 |
| 30 | Targeted therapy in sarcomas other than GIST tumors. <i>Journal of Surgical Oncology</i> , 2015, 111, 632-640. | 1.7 | 11 |
| 31 | HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. <i>Oncotarget</i> , 2015, 6, 31134-31150. | 1.8 | 38 |
| 32 | A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2014, 20, 5946-5955. | 7.0 | 72 |
| 33 | Understanding The Differential Response Of Multiple Myeloma To Reovirus Treatment. <i>Blood</i> , 2013, 122, 3232-3232. | 1.4 | 0 |